The Price of Principle: What PhRMA's GLOBE Lawsuit Reveals About the Future of Drug Pricing in America

There is a particular kind of lawsuit that tells you more about an industry's anxieties than its legal arguments. PhRMA's October 7 complaint against the Trump administration's GLOBE drug pricing model is one of them.

On the surface, the case is about statutory authority. The Pharmaceutical Research and Manufacturers of America filed suit in the U.S. District Court for the District of Columbia, arguing that the Centers for Medicare and Medicaid Services exceeded its legal mandate when it finalized the Global Benchmark for Efficient Drug Pricing model. GLOBE, which takes effect November 30 and begins its five-year test period in April 2027, would require manufacturers of certain high-expenditure Medicare Part B drugs to pay rebates benchmarked against prices in 19 other wealthy countries, including Canada, Germany, Japan, and the United Kingdom. PhRMA says CMS lacks the authority to do this. The agency says it does not.

But the deeper story here is not about administrative law. It is about what the pharmaceutical industry fears most: the normalization of international price referencing as a legitimate tool of American drug policy.

A Familiar Fight, With a New Twist

This is not the first time PhRMA has gone to court over most-favored-nation pricing. In 2020, the first Trump administration rushed out a similar rule without the required public comment period, and PhRMA successfully blocked it on procedural grounds. That victory was narrow and technical. This time, the legal challenge goes to the substance of whether CMS has the authority to adopt such a model at all, not just whether it followed the right process in doing so.

That distinction matters. A procedural win in 2020 left the underlying policy question unanswered. A substantive ruling this time, in either direction, would set a precedent with far longer legs. PhRMA's general counsel Jim Stansel put it plainly in an interview with Reuters: if courts do not foreclose the idea that CMS can use its demonstration model authority to impose drug pricing controls, then the floodgates open for future administrations to do the same.

The industry is not wrong to be concerned about precedent. The GLOBE model, as finalized, is actually quite limited in scope. CMS's own projections have collapsed from an initial estimate of $2.3 billion in annual savings to roughly $80 million per year, or about $440 million over the full payment period. The rule applies to only about 25 percent of Medicare Part B fee-for-service beneficiaries, selected by ZIP code. More than two dozen major drugmakers, including Pfizer, Eli Lilly, and Novo, have already signed voluntary White House pricing deals that exempt them from the model entirely. As few as four companies may ultimately be subject to it.

Why Fight a Rule That Barely Applies?

This is the question that cuts to the heart of the lawsuit's real purpose. If GLOBE is as toothless as the numbers suggest, why spend the legal fees and political capital to fight it?

The answer is that PhRMA is not fighting GLOBE. It is fighting what GLOBE represents. The model establishes, for the first time in a finalized federal rule, that international price benchmarking is a legitimate mechanism for setting Medicare drug payments. If that principle survives legal challenge and takes root in the regulatory landscape, it becomes the foundation for something much larger under a future administration less inclined to offer voluntary exemptions.

PhRMA's complaint also raises a pointed objection to the specific countries used as benchmarks. Several of them, including the United Kingdom, use quality-adjusted life years in their pricing and coverage decisions, a methodology that Congress has explicitly barred Medicare from using. The argument is that importing those countries' prices effectively imports their methodology through the back door, in violation of Section 1182 of the Social Security Act.

The Innovation Argument and Its Limits

PhRMA's public statements lean heavily on the innovation argument: price controls reduce R&D investment, which ultimately harms patients. Stephen Ubl, the outgoing CEO of PhRMA, framed the lawsuit as a defense of future medical breakthroughs. This argument has genuine merit in theory, and some empirical support in the literature. But it is also the industry's most overused rhetorical tool, deployed so reflexively in response to every pricing reform proposal that it has lost much of its persuasive force with policymakers and the public.

The more credible concern is narrower and more specific. GLOBE's rebate formula applies to antineoplastics, immunological agents, and ophthalmic agents with Part B spending above $100 million annually. These are precisely the categories where the most expensive and innovative drugs tend to cluster. If the model's benchmarks compress margins in these categories, the effect on investment incentives, while modest under the current rule, could become significant if the model is expanded or replicated in the companion Part D program, GUARD, which has yet to be finalized.

The litigation timeline is tight. GLOBE is set to take effect on November 30, and PhRMA has asked for a temporary restraining order to postpone that date. Briefing on preliminary relief is expected to move quickly. Whatever the court decides in the coming weeks will not just determine the fate of a limited Medicare demonstration model. It will draw a line, or decline to draw one, around how far the executive branch can go in reshaping drug pricing without an act of Congress. That is a question the pharmaceutical industry, and the patients who depend on it, have a genuine stake in getting right.